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Abstract
Two billion people worldwide are estimated to be latently infected with Mycobacterium tuberculosis (Mtb) and are at risk for
developing active tuberculosis since Mtb can reactivate to cause TB disease in immune-compromised hosts. Individuals with
latent Mtb infection (LTBI) and BCG-vaccinated individuals who are uninfected with Mtb, harbor antigen-specific memory
CD4
+ T cells. However, the differences between long-lived memory CD4
+ T cells induced by latent Mtb infection (LTBI)
versus BCG vaccination are unclear. In this study, we characterized the immune phenotype and functionality of antigen-
specific memory CD4
+ T cells in healthy BCG-vaccinated individuals who were either infected (LTBI) or uninfected (BCG) with
Mtb. Individuals were classified into LTBI and BCG groups based on IFN-c ELISPOT using cell wall antigens and ESAT-6/CFP-
10 peptides. We show that LTBI individuals harbored high frequencies of late-stage differentiated (CD45RA
2CD27
2)
antigen-specific effector memory CD4
+ T cells that expressed PD-1. In contrast, BCG individuals had primarily early-stage
(CD45RA
2CD27
+) cells with low PD-1 expression. CD27
+ and CD27
2 as well as PD-1
+ and PD-1
2 antigen-specific subsets
were polyfunctional, suggesting that loss of CD27 expression and up-regulation of PD-1 did not compromise their capacity
to produce IFN-c, TNF-a and IL-2. PD-1 was preferentially expressed on CD27
2 antigen-specific CD4
+ T cells, indicating that
PD-1 is associated with the stage of differentiation. Using statistical models, we determined that CD27 and PD-1 predicted
LTBI versus BCG status in healthy individuals and distinguished LTBI individuals from those who had clinically resolved Mtb
infection after anti-tuberculosis treatment. This study shows that CD4
+ memory responses induced by latent Mtb infection,
BCG vaccination and clinically resolved Mtb infection are immunologically distinct. Our data suggest that differentiation into
CD27
2PD-1
+ subsets in LTBI is driven by Mtb antigenic stimulation in vivo and that CD27 and PD-1 have the potential to
improve our ability to evaluate true LTBI status.
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Introduction
Tuberculosis (TB) remains a serious public health threat and
was responsible for about 1.4 million deaths in 2010 [1].
Remarkably, it has been estimated that 2 billion people worldwide
are latently infected with Mycobacterium tuberculosis (Mtb), with no
symptoms of disease [2]. While healthy individuals with latent Mtb
infection (LTBI) successfully control infection, Mtb can persist
within individuals for decades before reactivating to cause active
TB disease when the host is immune-compromised [3,4,5,6]. The
failure to fully clear bacteria in LTBI [6,7], therefore represents a
vast reservoir for increased transmission of TB, particularly in
populations co-infected with Human Immunodeficiency Virus
(HIV) [2,8,9]. Vaccination with Mycobacterium bovis Bacille Calm-
ette-Guerin (BCG) confers consistent and reliable protection
against miliary TB and TB meningitis in infants [10,11]. However,
BCG has variable - mostly poor- efficacy in protecting against
pulmonary TB disease in adults and children [12] and does not
prevent LTBI. In the United States, detection of LTBI in healthy
foreign-born persons is an important public health challenge as a
large proportion of foreign-born U.S. residents have a history of
BCG vaccination. It is estimated that 10–15 million individuals
have LTBI and that 63% of these individuals are foreign-born
[13,14]. Notably, BCG-vaccinated individuals who are uninfected
with Mtb as well as those who have LTBI can show positive
reactivity to the Tuberculin Skin Test (TST), which is widely used
for LTBI diagnosis. The TST is not specific for Mtb infection since
it measures memory responses to intradermal injection of Mtb
purified protein derivative (PPD), which cross-reacts with Mtb and
BCG strains. While both latent Mtb infection and BCG
vaccination can induce mycobacteria-specific memory CD4
+ T
cells in healthy individuals, the similarities and differences between
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+ T cell compartments induced by
LTBI versus BCG vaccination are unclear. Although Mtb-specific
interferon gamma release assays (IGRAs) like QuantiFERON and
T-SPOT.TB discriminate between LTBI and BCG vaccination,
they do not provide information about the phenotype and quality of
memory responses induced by latent Mtb infection or BCG
vaccination. We reasoned that detailed understanding of how LTBI
and BCG vaccination shape long-lived memory CD4
+ T cell
compartments in healthy individuals should provide important
insights into the nature of infection- and vaccine-induced immunity.
Several studies have established that the production of Th1
cytokines like IFN-c and TNF-a by antigen-specific CD4
+ T cells
is critical for controlling Mtb infection and containing bacteria
within lung granulomas [15,16]. Indeed, lowering of CD4
+ counts
is known to significantly increase the risk of TB disease [17]. CD4
+
T cells that survive the acute phase of infection are retained as
memory cells and Mtb-specific memory CD4
+ T cells are central
to prevent progression to TB in healthy latently infected
individuals [15,16]. Polyfunctional CD4
+ T cells that simulta-
neously express the three cytokines IFN-c, TNF-a and IL-2 are
thought to be associated with the control of intracellular pathogens
[18] including Mtb [19]. Furthermore, many studies have revealed
that the differentiation and function of memory T cell subsets in
healthy individuals is directly shaped by antigenic stimulation
induced by vaccination or latent viral infection [20,21,22].
However, we lack detailed insights into how the immune
phenotype and quality of long-lived memory CD4
+ T cell
compartments in healthy individuals is shaped and influenced by
latent Mtb infection versus BCG vaccination.
In this study, we performed detailed characterization of the
immune phenotype and functionality of antigen-specific memory
CD4
+ T cells in healthy BCG-vaccinated individuals who were
either infected (LTBI) or uninfected with Mtb (BCG). We show that
CD27 and PD-1 expression on antigen-specific memory CD4
+ T
cells could predict LTBI versus BCG status in healthy individuals.
Interestingly, we found that CD27 and PD-1 also distinguish LTBI
individuals from those who have clinically resolved Mtb infection
after anti-tuberculosis treatment. These studies show that the CD4
+
memory responses induced by latent Mtb infection, BCG
vaccination and clinically resolved Mtb infection are immunolog-
ically distinct and suggest that differentiation into CD27
2 PD-1
+
subsets is driven by persistent antigenic stimulation by Mtb in vivo.
CD27 and PD-1 have the potential to improve our ability to
evaluate Mtb infection status in healthy individuals.
Results
IFN-c Elispot to identify individuals with memory
responses to Mtb infection
Using IFN-c ELISPOT assays, we screened PBMCs from 80
healthy adults for reactivity to Mtb CW antigens, which are a
mixture of Mtb cell wall components [23], and to peptide pools
derived from the Mtb-specific proteins ESAT-6 and CFP-10. All
enrolled individuals were born outside the United States and had
BCG vaccination histories. CW antigens cross-react with the M.
bovis BCG strain and therefore CW-specific memory responses will
be present in individuals who were latently infected with Mtb
(LTBI) as well as in BCG-vaccinated individuals (BCG) that are
not infected with Mtb. Therefore, only individuals with Mtb-
specific memory T cells will respond to stimulation with ESAT-6
and CFP-10 peptide. Figure 1 shows that individuals were
classified as LTBI (n=20) when they showed Mtb-specific
memory T cell responses, i.e. they had positive responses to both
CW and ESAT-6/CFP-10 peptides. Those that showed reactivity
to CW antigens but not to ESAT-6/CFP-10 peptides were
classified as BCG (n=20). While both LTBI and BCG groups
exhibited strong IFN-c responses to CW antigens, individuals in
the LTBI group had higher frequencies of antigen-specific cells as
reflected by the percentages of spot forming cells (SFC) in the
Elispot assay (Fig. 1). Among BCG-vaccinated individuals tested,
40 were not further studied as they showed no reactivity to any of
the mycobacterial antigens tested, consistent with the documented
waning of immune memory in BCG-vaccinated individuals over
time [24]. Five non-BCG-vaccinated healthy individuals who did
not show reactivity to either CW or ESAT-6/CFP-10 peptides
served as negative controls (Fig. S1).
Phenotypic and functional characterization of CD4
+ T
cells in LTBI and BCG individuals
We used multi-parameter flow cytometry for detailed immuno-
phenotypic analyses to evaluate the quality of long-lived Mtb-
specific memory CD4
+ T cells in PBMC from the LTBI and BCG
groups. We assessed their homeostatic turnover, differentiation
state and cytokine production upon stimulation with Mtb CW
antigen. Representative data are shown in Fig. 2A and
summarized in Fig. 2B. Memory CD4
+ T cells in both groups
were in a resting state as they did not express CD38 and HLA-DR,
which are markers of immune activation [20,25], and were in a
non-cycling state as they were negative for Ki-67, which is
associated with cycling T cells [26]. The expression of the anti-
apoptotic protein Bcl-2 suggests that these cells were not destined
to undergo apoptosis [27]. Both LTBI and BCG groups harbored
effector memory subsets as indicated by expression of CD127 (IL-
7Ra), which is selectively re-expressed on memory T cells [28], but
no co-expression of CCR7, a chemokine receptor that is expressed
preferentially on central memory subsets [29]. Examination of the
differentiation state of the antigen-specific effector memory CD4
+
T cells in LTBI and BCG groups showed that both exhibited a
CD45RA
2 CD28
+ phenotype (Fig. 2A, B). However, expression
of the costimulatory marker CD27 was heterogeneous between
LTBI and BCG groups (Fig. 2A–C). Since loss of CD27
expression denotes late-stage differentiation during the step-wise
Figure 1. Identification of LTBI individuals by IFN-c ELISPOT
assays. PBMC isolated from 40 healthy BCG-vaccinated individuals
were stimulated with Mtb cell wall antigens (CW) or peptide pools
derived from Mtb-specific proteins ESAT-6 and CFP-10 (10 mg/ml). Data
are represented as spot forming cells (SFC) per 2610
5 PBMC. Each data
point corresponds to a single donor.
doi:10.1371/journal.pone.0036046.g001
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[30,31,32], our data suggest that the presence of antigen in LTBI
drives maturation of effector memory CD4
+ T cells to later stages
of differentiation than in the BCG group.
We next assessed the ability of CW-specific memory CD4
+ T
cells from LTBI and BCG groups to simultaneously express IFN-c,
TNF-a and IL-2 (Fig. 3A). This analysis categorized cytokine-
positive cells into seven different subsets consisting of triple (3+),
double (2+) and single (1+) cytokine-producing populations
(Fig. 3B). The expression patterns of 3+,2 + and 1+ were similar
between LTBI and BCG although the BCG group had lower
frequencies of antigen-specific cytokine-producing cells (Fig. 3A,
B). Polyfunctional cytokine-producing cells that simultaneously
produced IFN-c, TNF-a and IL-2 dominated the cytokine
response in both LTBI and BCG individuals. Cells expressing
IFN-c/TNF-a dominated the 2+ populations (,90%) and ,60%
of the 1+ populations corresponded to TNF-a producers.
CD27
+ and CD27
2 antigen-specific effector memory
CD4
+ T cells exhibit polyfunctional cytokine responses in
LTBI and BCG individuals
To assess whether CD27 expression influences the functional
capacity of antigen-specific memory CD4
+ T cells, we compared
the functional capacities of CD27
+ and CD27
2 subsets in BCG
and LTBI individuals. Both CD27
+ and CD27
2 subsets were
capable of producing IFN-c, TNF-a and IL-2 in response to
antigenic stimulation. Figure 4A shows that LTBI individuals had
higher frequencies of CD27
2 late-stage differentiated antigen-
specific memory CD4
+ T cells (,50%), compared to the BCG
group which had only ,20% (p,0.0001). Moreover, both CD27
+
and CD27
2 subsets in LTBI displayed similar polyfunctional
cytokine profiles (Fig. 4B). The expression patterns of 3+ account
for 49–51%, 2+ for 18–20% and 1+ for 30–33% of the total
cytokine response. Cells expressing IFN-c/TNF-a were dominant
(,80%) among the 2+ populations and cells expressing only TNF-
a were dominant (,60%) among the 1+ populations (Fig. 4B).
Figure 2. Characterization of Mtb antigen-specific memory CD4
+ T cells in LTBI and BCG individuals using multiparameter flow
cytometry. (A) Immunophenotyping of memory CD4
+ T cells from LTBI and BCG individuals. Data from two representative donors are shown. The
indicated cell surface markers on CW-stimulated PBMC gated on total CD4
+ T cells were assessed by flow cytometry (black) and on IFN-c producing
cells were assayed by intracellular staining (red). (B) Graphical summary of immunophenotypic analyses. The expression of each marker is expressed
as a percentage of the total antigen-specific IFN-c
+ CD4
+ T cells in LTBI (n=18) and BCG (n=18) groups (C). Expression of CD27 on antigen-specific
memory CD4
+ T cells from LTBI (n=18) and BCG (n=18). The percentage of antigen-specific CD4
+ T cells is significantly different in LTBI and BCG
groups (p,0.0001).
doi:10.1371/journal.pone.0036046.g002
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presence of antigen drives maturation of effector memory CD4
+ T
cells to later stages of differentiation than in the BCG group, our
data indicate that this loss does not compromise the functional
capacity of these CD4
+ T cells.
High frequencies of PD-1-expressing Mtb-specific CD4
+ T
cells in LTBI
To further investigate whether the late-stage differentiation of
the antigen-specific CD4
+ T cells in LTBI is shaped by the
presence of Mtb, we examined the expression of PD-1 [33,34,35].
We assessed PD-1 expression on antigen-specific CD4
+ T cells
from LTBI and BCG individuals and found that the frequencies of
PD-1 expression on IFN-c-producing CD4
+ T cells were
significantly higher in LTBI than BCG individuals. The mean
frequency of PD-1
+ CD4
+ T cells in LTBI was 2.3-fold greater
than in the BCG group (mean6SEM 29.062.6% vs 12.560.7%,
p,0.0001) (Fig. 5A, B). Similarly, the PD-1 mean fluorescence
intensity (MFI) on antigen-specific IFN-c
+ CD4
+ T cells was
significantly higher in LTBI compared to BCG (mean6SEM
1129652 vs 728633; p,0.0001) (Fig. 5C). Overall, the antigen-
specific CD4
+ T cells show intermediate levels of PD-1 expression.
There was no significant difference in PD-1 expression on bulk
CD4
+ T cells from LTBI and BCG groups (Fig. S2). The PD-1
expression shown in Figure 5A and 5B is not a result of up-
regulation in cell culture as PD-1 was not induced ex vivo in LTBI
or BCG groups until 48 hours of stimulation (data not shown).
Since PD-1 expression has been shown to correlate with antigen
presence, these data suggest that the higher frequencies of PD-1-
expessing memory CD4
+ T cells in LTBI compared to the BCG
group reflect ongoing antigenic stimulation of memory CD4
+ T
cells in LTBI.
To examine whether PD-1 expression influences the capacity of
antigen-specific cells to produce these cytokines, we analyzed the
cytokine profile of PD-1
+ and PD-1
2 effector memory popula-
tions. We found that both PD-1
+ and PD-1
2 cells produce IFN-c,
TNF-a and IL-2 in response to CW stimulation and are
polyfunctional (Fig. 5D, E). The 3+ profile was predominant in
both groups (,50%) followed by 2+ (,25%) and 1+ (,25%). The
frequency of cells with the 3+ cytokine profile was ,2-fold lower in
PD-1
+ compared to PD-1
2 (p=0.01) (Fig. 5D, E). These data
demonstrate that intermediate levels of PD-1 expression in healthy
LTBI individuals do not impact the capacity of CD4
+ T cells to
produce IFN-c, TNF-a and IL-2 upon stimulation.
PD-1 expression correlates with loss of CD27 expression
on antigen-specific CD4
+ T cells
We have shown that in LTBI, ,50% of the CCR7
2CD45RA
2
subsets have lost CD27 expression and are therefore in late stages
of antigen-driven memory CD4
+ T cell differentiation. Moreover,
a significant proportion of the memory CD4
+ T cells express PD-
1, which is typically induced by the antigen presence. We next
investigated the relationship between PD-1 and CD27 on antigen-
specific IFN-c
+ memory CD4
+ T cells in LTBI. We examined the
Figure 3. Cytokines production by effector memory CD4
+ T cells from LTBI and BCG individuals. (A) Functional profile of IFN-c, IL-2 and
TNF-a CD4
+ T cells are shown in representative LTBI and BCG individuals. (B) Polyfunctional cytokine production by memory CD4
+ T cells from LTBI
and BCG. Data are represented as the mean percentage of responding CD4
+ T cells that are triple producers (3+), double producers (2+) or single
producers (1+) of IFN-c, TNF-a, and IL-2 and summarized by the pie charts. Each slice of the pie represents the fractions of the total response that
consists of CD4
+ T cells positive for a given function.
doi:10.1371/journal.pone.0036046.g003
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+ and PD-1
2 antigen-specific
IFN-c
+ CD4
+ T cells in LTBI individuals (Fig. 6A). We observed
that CD27
+ subsets were higher in PD-1
2 T cells compared to
PD-1
+ (mean6SEM 59.5%63.2 vs 41.4%63.1, p,0.0003)
(Fig. 6B), indicating that in LTBI, PD-1
+ T cells are more
differentiated than PD-1
2 antigen-specific memory CD4
+ T cells.
Consistent with these observations, we found a significant inverse
correlation between the expression of PD-1 and the expression of
CD27 on IFN-c-producing CD4
+ T cells across LTBI and BCG
groups (r,20.69, p,0.0001) (Fig. 6C). Late-stage differentiated
CD27
2 PD-1
+IFN-c
+ cells were more likely to be associated with
LTBI individuals while the early/intermediate-stage differentiated
CD27
+ PD-1
2IFN-c
+ cells were more likely to be associated with
BCG individuals (Fig. 6C). These data suggest that PD-1
expression correlates with the stage of differentiation.
CD27 and PD-1 expression predict LTBI versus BCG status
and distinguish latent infection from clinically resolved
Mtb infection
Our data show that LTBI is characterized by high frequencies
of PD-1
+CD27
2 antigen-specific effector memory subsets while
BCG-vaccinated individuals have predominantly PD-1
2 CD27
+
antigen-specific subsets (Fig. 7A). We used statistical models to
evaluate the utility of CD27 and PD-1 in predicting LTBI versus
BCG status in healthy individuals. To evaluate the predictive value
of CD27 and PD-1 individually, we used Receiver Operating
Characteristic (ROC) curve analysis and logistic regression for
both markers in combination. We found that either CD27 or PD-1
or both in combination correctly identify LTBI and BCG groups
with high predictive values (AUC=0.994, 0.906 and 0.993;
respectively), indicating that either CD27 or PD-1, or both
markers, can discriminate between the two groups (Fig. 7A).
The diagnosis of LTBI is based on information gathered from
the medical history of an individual, TST and/or IGRA results,
chest radiograph, physical examination and in certain circum-
stances, sputum examinations to rule out active TB. However,
individuals who have successfully completed anti-tuberculosis
treatment remain TST and/or IGRA positive and cannot be
distinguished from LTBI by diagnostic tests alone. We next
investigated the ability of CD27 and PD-1 to discriminate between
LTBI individuals and healthy individuals who were previously
treated for TB and have clinically resolved Mtb infection. We also
included the BCG individuals in this investigation. Healthy TB
treated individuals who were asymptomatic and sputum-negative
were enrolled $2 years after completing treatment for active TB.
Figure 7B shows a graphical representation of the frequencies of
Figure 4. CD27
+ and CD27
2 antigen-specific memory CD4
+ T cell subsets are polyfunctional. (A) Distribution of CD27
+ and CD27
2
memory CD4
+ T cells from LTBI (n=12) and BCG (n=9) that produce IFN-c, TNF-a or IL-2 upon stimulation with CW antigen. The antigen-specific T
cells are CD28
+, CCR7
2 and CD45RA
2. Each data point corresponds to a single donor. (B) Polyfunctional cytokine responses from CD27
+ and CD27
2
subsets in LTBI. Data are represented as the mean percentage of responding CD4
+ T cells that are triple producers (3+), double producers (2+)o r
single producers (1+) of IFN-c, TNF-a, and IL-2 and summarized by the pie charts. Each slice of the pie represents the fractions of the total response
that consists of CD4
+ T cells positive for a given function.
doi:10.1371/journal.pone.0036046.g004
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+ and CD27
+ antigen-specific memory CD4
+ T cells in LTBI
versus TB treated individuals. Using ROC analysis, we found that
PD-1 alone effectively distinguished TB-treated individuals from
LTBI (AUC=0.875), suggesting that PD-1 may have utility as a
marker of Mtb presence (Fig. 7B). CD27 was slightly less effective
when tested singly (AUC=0.732). However the predictive value of
PD-1 when tested in combination with CD27 improved
(AUC=0.885) (Fig. 7B). In contrast, PD-1 was less informative
in distinguishing between BCG and TB-treated individuals
(AUC=0.581) (Fig. 7C). This was consistent with the low
frequencies of PD-1
+ antigen-specific T cells in BCG and TB treated
groups (Fig. 7C). However, CD27 does appear to have some utility
in distinguishing BCG and TB treated individuals (AUC=0.765),
which increases slightly in combination with PD-1 (AUC=0.814)
(Fig. 7C). In conclusion, these models suggest that PD-1 and CD27
in combination are potential markers for distinguishing healthy
individuals with latent Mtb infection (LTBI) from healthy individuals
who have been previously treated for Mtb infection.
Figure 5. Higher frequencies of PD-1 expression on antigen-specific memory CD4
+ T cells in LTBI relative to BCG individuals. (A) A
representative plot of CD4
+ T cells expressing PD-1 upon CW stimulation, displaying the percentage of antigen-specific IFN-c producing cells. The
summary of percentage (B) and MFI (C) of PD-1 expression on antigen-specific memory CD4
+ T cells in LTBI (n=18) and BCG (n=18) groups. Each
data point corresponds to a single donor. Polyfunctional cytokine production by memory PD-1
+ (D) and PD-1
2 (E) T cells from LTBI. Data are
represented as the mean percentage of responding PD-1
+ or PD-1
2 T cells that are triple producers (3+), double producers (2+) or single producers
(1+) of IFN-c, TNF-a, and IL-2 and summarized by the pie charts. Each slice of the pie represents the fractions of the total response that consists of PD-
1
+ or PD-1
2 cells positive for a given function.
doi:10.1371/journal.pone.0036046.g005
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Latent infection with Mtb poses a threat to public health
globally due to the presumed persistence of Mtb in vivo, which can
lead to TB reactivation [3,4,5,6]. CD4
+ T cells have been shown
to play a role in the control of Mtb infection [36]. In this study, we
investigated how Mtb infection shapes the quality of the memory
CD4
+ T cells during latency by comparing the immune phenotype
and function of long-lived antigen-specific memory CD4
+ T cells
in healthy BCG-vaccinated individuals who were either uninfected
(BCG) or infected with Mtb (LTBI). We used Mtb cell wall (CW)
antigens for stimulation of PBMCs from these two groups as the
cell wall plays a critical role in Mtb intracellular survival,
persistence, and pathogenicity, and provides a rich source of
diverse antigens for immune recognition [37,38].
LTBI and BCG individuals harbored resting, non-cycling
effector memory populations that were not destined for apoptosis.
This finding is in agreement with the idea that effector memory T
cells in LTBI may reflect the continued presence of live, non-
replicating bacteria [39]. Comparison of cytokine-expressing
CD4
+ T cells revealed significantly higher percentages for IFN-
c, TNF-a and IL-2 cells in LTBI as compared to BCG group.
However, the long-lived memory CD4
+ T cells in both groups had
similar cytokine profiles that were predominantly polyfunctional
with respect to IFN-c, TNF-a and IL-2 production after CW
stimulation. These results in LTBI were in agreement with recent
studies in which similar proportions were detected using PPD,
which is also a mixture of Mtb antigens [40,41]. However, these
results contrast with data using latency-associated antigens where
predominantly monofunctional CD4
+ T cells were reported
Figure 6. PD-1 expression correlates with loss of CD27 expression on antigen-specific memory CD4
+ T cells. (A) Gating strategy and
representative histograms showing CD27 expression on PD-1
+ and PD-1
2 antigen-specific IFN-c
+ CD4
+ T cells in PBMC from one LTBI individual
stimulated with CW antigens. (B) Frequencies of CD27
+ and CD27
2 subsets on PD-1
+ and PD-1
2 antigen-specific IFN-c
+ CD4
+ T cells in LTBI
individuals (n=16) (C) PD-1 expression is inversely correlated with CD27 expression on antigen-specific CD4
+ T cells from LTBI (n=16) and BCG
(n=17) individuals (r=20.69, p,0.0001). Circles highlight the data points corresponding to LTBI and BCG individuals.
doi:10.1371/journal.pone.0036046.g006
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infections have suggested that polyfunctional T cells that produce
multiple cytokines are more likely to provide protective immunity
than T cells that produce a single cytokine [21]. While
polyfunctional memory CD4
+ T cells have been detected in
healthy individuals with LTBI [40,41,44,45,46,47,48] and in
BCG-vaccinated infants [49]; their role in providing protective
immunity against TB remains unclear [19].
The major phenotypic difference between the LTBI and BCG
groups was the expression of the costimulatory marker CD27 on
antigen-specific memory CD4
+ T cells. LTBI individuals harbored
significantly higher frequencies of antigen-specific effector memory
CD4
+ T cells that had lost CD27 expression. Since loss of CD27
has been shown to be associated with antigen-induced maturation
of effector memory subsets [31], these results suggest that the
presence of Mtb in LTBI drives these subsets to later stage of
differentiation than seen in the BCG group. This finding is in
agreement with a previous study which showed that patients with
smear and/or culture positive pulmonary TB had the highest
percentages of CD27
2 tuberculin-reactive CD4
+ T cells followed
by LTBI and then BCG-vaccinated individuals [50]. In addition,
we show that whereas polyfunctional cytokine production in BCG
individuals is mainly associated with CD27
+, in LTBI both CD27
+
and CD27
2 subsets are polyfunctional, suggesting that CD27 does
not reflect functional capacity. The memory CD4
+ T cell
phenotype in LTBI is distinct from latent cytomegalovirus
(CMV) infection, where antigen-driven accumulation of terminally
differentiated, CD27
2 CD45RA
+ effector memory CD4
+ T cells
have been described [51,52]. Unlike the poorly proliferating
CD27
2 CD45RA
+ T cells as well as CD27
2 CD45RA
2 T cells in
latent CMV infection [53,54], the CD27
2 CD45RA
2 subsets in
LTBI display robust proliferative capacity in vitro in response to
stimulation with CW antigens (T.A. and J.R., unpublished data).
While latency-associated antigens have been shown to potentially
be useful to discriminate between different stages of TB based on
IFN-c frequencies, the phenotypes of these antigen specific T cells
in PBMCs or at the site of infection have not yet been elucidated
[55,56,57,58,59].
PD-1 is a co-inhibitory receptor that is up-regulated on
activated antigen-specific effector T cells in viral infections where
it has been implicated in promoting dysfunctional responses
[34,35,60]. PD-1 has also been shown to be expressed on Mtb-
specific effector T cells in active TB patients [33]. In our study, the
expression of PD-1 on antigen-specific memory CD4
+ T cells is
Figure 7. Statistical modeling to evaluate the predictive value of CD27 and PD-1 in healthy individuals. The frequencies of PD-1
+ IFN-c
+
and CD27
+ IFN-c
+ T cells for the following pairs (A) LTBI versus BCG, (B) LTBI versus TB-treated and (C) BCG versus TB-treated, are graphically
represented. Receiver Operating Characteristic (ROC) curve analysis and logistic regression models were used to evaluate the predictive value of
CD27 and PD-1 individually and in combination. The area under the curve (AUC) indicates the predictive value for each marker.
doi:10.1371/journal.pone.0036046.g007
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suggesting that PD-1 expression may correlate with the presence
of Mtb in latent TB. Our studies on PD-1 expression in latent Mtb
infection show similarities to a recent report on latent viral
infections [61]. This study showed that in healthy individuals with
latent viral infections, PD-1 was expressed on functional EBV-and
CMV- specific memory CD8
+ T cells. In contrast, in cleared viral
infections, PD-1 expression on influenza- and vaccinia-specific
memory CD8
+ T cells was significantly lower [61]. In LTBI, we
found that antigen-specific PD-1
+ T cells are polyfunctional
suggesting that PD-1 expression does not affect the ability of CD4
+
T cells to produce IFN-c, TNF-a and IL-2. Similar results have
been reported for SIV-specific CD8
+ T cells [62]. Furthermore,
the observed spread in the frequencies of PD-1
+IFN-c
+ cells in
LTBI is reminiscent of observations in non-human primate models
where LTBI is represented by a spectrum of granulomatous lesions
in the lungs of cynomolgus macaques [63]. Our study raises the
interesting speculation that PD-1 levels on antigen-specific effector
memory CD4
+ T cells may reflect the proposed spectrum of
latency in humans [6,64,65]. Interestingly, we found that PD-1
was preferentially expressed on cells that had lost CD27 expression
and was therefore associated with the differentiation stage of CD4
+
T cells. Moreover, there was a significant inverse correlation
between the expression of PD-1 and CD27 across LTBI and BCG
groups. Similar results have been reported in HIV infection where
PD-1 expression was linked to the differentiation stage and
activation status of HIV-specific CD8
+ T cells [66].
Overall, our data suggest that the presence of CD27
2PD-1
+
antigen-specific effector memory CD4
+ T cells may reflect
persistent Mtb antigen stimulation in vivo. Alternatively, the
heterogeneous expression of CD27 and PD-1 in LTBI and BCG
groups may reflect the inherent phenotypic differences between
the immune responses induced by Mtb and BCG at the time of
infection or vaccination, which result in long-lived antigen-specific
memory responses. This should be considered when developing
new vaccines against TB. We also show, using ROC curve analysis
and logistic regression models, that CD27 and PD-1 could predict
LTBI and BCG status in healthy individuals. CD27 and PD-1 in
combination also distinguish LTBI from healthy individuals who
have been previously treated for TB and have successfully resolved
Mtb infection. While our observations based on in vitro antigenic
stimulation of PBMCs from LTBI, BCG and TB treated
individuals do not necessarily reflect the in vivo situation within
these individuals, they nonetheless provide a useful assay for
discriminating between these sub-groups of healthy individuals.
Our studies reinforce the advantages of T cell-based diagnostics
like QuantiFERON and T-SPOT.TB over TSTs for identifying
LTBI in BCG-vaccinated populations. Notably, while these assays
eliminate issues of BCG cross-reactivity [4,65], they do not
distinguish LTBI individuals from healthy individuals who have
been previously treated for TB. Incorporating CD27 and PD-1 as
additional markers in T cell based assays thus has the potential to
substantially improve our ability to evaluate true LTBI status. In
the U.S., where 10–15 million individuals are estimated to have
LTBI, targeting preventive treatment to the subset of individuals
who are most likely to harbor Mtb in vivo is an important goal for
TB control efforts.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Ethical approval was obtained from
the Emory University Institutional Review Board and all
participants were provided written informed consent for the
collection of samples and subsequent analyses.
Study participants and PBMC isolation
Eighty healthy asymptomatic individuals (23 to 55 years of age)
who have BCG vaccination histories were recruited at Emory
University, Atlanta, GA. These individuals had no history of active
tuberculosis, no recent history of severe respiratory diseases, a
normal chest X-ray, and were anti-tuberculosis treatment-naı ¨ve
and HIV negative. Twelve individuals who were previously
treated for pulmonary active TB were recruited from Grady
Hospital in Atlanta, GA. These individuals were originally
diagnosed as to have active pulmonary TB by positive chest X-
ray, positive sputum smear and/or culture and/or nucleic acid
amplification tests. At the time of enrollment in the study, all TB-
treated individuals were HIV negative, sputum-negative and had
normal chest X-ray and were enrolled $2 years after completion
of anti-tuberculosis treatment. Their status was confirmed by
assaying for the presence of IFN-c
+ CD4
+ T cells by intracellular
cytokine staining in PBMCs stimulated with Mtb CW antigen and
ESAT-6/CFP-10 peptide pools and compared with the profile of
non-stimulated cells. Five non-BCG-vaccinated healthy individu-
als with no history of Mtb exposure were also recruited as controls.
PBMC were isolated from blood using cell preparation tubes
(CPT, BD Biosciences) and cryopreserved in 90% fetal FBS
(Hyclone, South Logan, UT) and 10% dimethyl sulfoxide (Sigma-
Aldrich, St. Louis, MO).
IFN-c ELISPOT assays
All antibodies for ELISPOT assays were purchased from
Mabtech (Cincinnati, OH) and performed according to standard
procedures. PBMC were plated in triplicate at 2610
5 cells/well
and stimulated for 24 h at 37uC with 5 mg/ml Mtb cell wall (CW)
antigens (NIH-TBVRM contract, Colorado State University),
5 mg/ml ESAT-6 and CFP-10 peptide pools synthesized by
Genemed Synthesis Inc., (San Antonio, TX), as previously
described [67]; 1 mg/ml SEB as the positive control or medium
as the negative control. Spot-forming cells (SFCs) were counted on
an automated ELISPOT reader (CTL series 3A analyzer, Cellular
Technology, Cleveland, OH) and analyzed with Immunospot
(CTL Analyzers). Responses were scored as positive if the test wells
contained a mean of at least 10 SFCs more than the mean of the
negative control wells.
Cell stimulation, staining and flow cytometry
Before stimulation, cryopreserved PBMC were thawed and
resuspended overnight at 37uC, 5% CO2 in RPMI-1640 medium
(Lonza, Walkersville, MD) containing 10% FBS, 2 mM glutamine,
100 IU/ml penicillin, and 100 mg/ml streptomycin. The viability
of the lymphocytes was 80–95%. 1610
6 PBMC were each
stimulated with CW antigens (10 mg/ml) and ESAT-6 and CFP-10
peptides (10 mg/ml) at 37uC, 5% CO2 for 2 h followed by the
addition of Brefeldin A (10 mg/ml) (BD Biosciences, San Diego,
CA) and further incubated for 16 h. PBMC were washed, surface-
stained with appropriate antibodies, permeabilized with Cytofix/
Cytoperm Kit (BD Biosciences), stained intracellularly with
appropriate antibodies: IFN-c (clone B27), TNF-a (clone
Mab11), IL-2 (clone MQ1-17H12), Ki-67 (clone B56), Bcl-2
(clone Bcl-2/100) and fixed with 1% paraformaldehyde before
acquisition on a FACSCalibur (BD BioSciences) or LSR-II system
(BD Biosciences). Monoclonal antibodies were obtained from BD
Biosciences, eBiosciences (San Diego, CA), Beckman-Coulter
(Fullerton, CA), R&D Systems (Minneapolis, MN) and Biolegend
(San Diego, CA). FACS data were analyzed with FlowJo software
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analysis, CD4
+ T cells were gated on cytokine-positive cells.
Boolean combination gating was performed to calculate the
frequencies corresponding to seven different combinations of
cytokines.
Statistical analysis
Statistical analyses were performed using Graphpad Prism 4.0
software; the Mann-Whitney U test and the unpaired t-test were
used. A p-value of less than 0.05 was considered to be statistically
significant. The Pearson correlation test was used for correlation
analysis. For the predictive models, data analysis was performed in
the statistical software R [68]. For single marker analysis, Receiver
Operating Characteristic (ROC) curve analysis was used which
plots sensitivity (true positive rates) versus 1-specificity (false
positive rates) for each marker individually. The area under curve
(AUC) was determined by numerical integration for each marker
[69] to evaluate the predictive value of the marker. An AUC value
of 1 indicates the maximum predictive value for a given marker.
To combine both markers for prediction, logistic regression was
performed and the associated ROC was plotted, where the
sensitivity and specificity were found as a function of the
probability cutoff.
Supporting Information
Figure S1 CD4
+ T cells from healthy controls (non-BCG-
vaccinated donors) do not show IFN-c
+ reactivity to Mtb
CW antigens. PBMC from healthy controls or LTBI donors
were either not stimulated (NS) or stimulated with CW or SEB and
stained for flow cytometric analysis as described in the Methods.
(TIF)
Figure S2 PD-1 levels on unstimulated PBMC do not
differ between LTBI, BCG and TB treated groups. PBMC
from each of the three groups LTBI, BCG, TB-treated) were
stained with PD-1 and analyzed by flow cytometry. No significant
differences in the frequencies of PD-1-expressing CD4
+ T cells
were observed.
(TIF)
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